AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Wall Street Bulls Look Optimistic About Astrazeneca (AZN): Should You Buy?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease
The FDA okays AstraZeneca's Fasenra for treating adults with eosinophilic granulomatosis with polyangiitis. This is the second approved indication for the drug.
AstraZeneca PLC (AZN) Meet the Management at ESMO 2024 Conference (Transcript)
AstraZeneca PLC (NASDAQ:AZN ) Meet the Management at ESMO 2024 Conference September 16, 2024 2:00 PM ET Company Participants Pascal Soriot - Chief Executive Officer Susan Galbraith - EVP, Oncology R&D Thomas Powles - Professor of Genitourinary Oncology; Director, Barts Cancer Centre Sunil Verma - SVP, Global Head, Oncology Franchise Dave Fredrickson - EVP, Oncology Business Matt Hellmann - VP, Early Oncology Development Cristian Massacesi - Chief Medical Officer, Chief Development Officer Oncology Melissa Scaltrisi - Head of Traditional Medicine Leora Horn - Global Clinical Strategy Head for Lung Conference Call Participants Tony Ryan - Macquarie Emily Field - Barclays Christopher Uhde – SEB Simon Baker - Redburn Sam Fazeli - Bloomberg Intelligence Alana Lelo - Guggenheim Richard Parks - BNP Paribas Exane Andrew Berens - Leerink Partners Etzer Darout - BMO Capital Markets Gonzalo Artiach - Danske Bank Mattias Haggblom - Handelsbanken James Gordon - JPMorgan Luisa Hector - Berenberg Rajan Sharma - Goldman Sachs Operator Welcome, ladies and gentlemen, to AstraZeneca's Investor Conference Call ESMO 2024. Before I hand over to AstraZeneca's management team, I'd like to read the safe harbor statement.
AstraZeneca Stock Downgraded on Drug Trial Results
Biopharmaceutical stock AstraZeneca PLC (NASDAQ:AZN) is 1.3% lower before the open, after a bear note from Deutsche Bank.
AstraZeneca: Dato-DXd Should Still Be Approved In Q4 Despite Underwhelming Data
AstraZeneca's Dato-DXd showed disappointing overall survival data in the TROPION-Lung01 phase 3 trial. Dato-DXd's progression-free survival benefit, especially in biomarker-positive patients, and the totality of the data, support its potential approval despite underwhelming overall survival results. AstraZeneca has many additional shots on goal with Dato-DXd across first and second line+ lung cancer and breast cancer.
AstraZeneca Faces Setback From Lung Cancer Drug's Disappointing Trial Results
A Phase 3 trial found AstraZeneca's (AZN) experimental lung cancer drug datopotamab deruxtecan (Dato-DXd) did not significantly improve patients' overall survival rates.
AstraZeneca falls as cancer drug disappoints, analysts cuts FDA approval chances
Shares in AstraZeneca PLC (LSE:AZN) were the biggest drag on the FTSE 100 on Tuesday, falling over 4.5% on the back of some disappointing results from a trial of a lung cancer drug. Late-stage trial results of the TROPION-Lung01 showed that the overall survival rate from the new drug “did not reach statistical significance,” the company said.
AstraZeneca shares fall 5% on disappointing lung cancer drug trial results
AstraZeneca shares fell more than 5% Tuesday morning, the biggest one-day drop in seven months, after the British pharmaceutical giant announced disappointing lung cancer drug trial results.
AstraZeneca shares drop as lung cancer drug trial fails to improve survival
London-listed shares of AstraZeneca fell on Tuesday after results from the company's lung cancer trials showed that its experimental precision drug did not significantly improve overall survival results for patients.
AstraZeneca says lung cancer drug trial shows no significant improvement in overall survival
Detailed results from one of AstraZeneca's key lung cancer trials released on Monday showed that its experimental precision drug did not significantly improve overall survival results for patients in the trial.
3 Market-Beating Stocks to Buy for Less Than $100
AstraZeneca's robust pipeline and plentiful growth opportunities make it one of the best healthcare stocks to buy. Chewy is coming off a solid quarter, and there's still more growth ahead in the pet food industry.
AstraZeneca Employees Held in China for Drug-Import, Data Privacy Investigations
Five current and former AstraZeneca (AZN) employees have been detained by police in China in connection with alleged violations of data privacy laws and for importing an unapproved cancer drug, according to a Bloomberg report.
